发布求助
文献互助 智能选刊 最新文献

Nature Reviews Clinical Oncology最新文献

筛选
英文 中文
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA Zanidatamab有望成为晚期HER2+ GEA的一线治疗药物
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-06-18 DOI: 10.1038/s41571-025-01048-4
David Killock
{"title":"Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA","authors":"David Killock","doi":"10.1038/s41571-025-01048-4","DOIUrl":"https://doi.org/10.1038/s41571-025-01048-4","url":null,"abstract":"<p>Trastuzumab plus platinum–fluoropyrimidine chemotherapy has been the backbone of frontline therapy for advanced-stage HER2-positive gastroesophageal adenocarcinoma (HER2<sup>+</sup> GEA) since 2010 on the basis of results from the landmark phase III ToGA trial. Now, data from a phase II trial indicate that zanidatamab, a biparatopic antibody targeting two distinct epitopes of HER2, might improve outcomes in this setting.</p><p>In this single-arm trial, patients with previously untreated advanced-stage HER2<sup>+</sup> GEA received zanidatamab in combination with either 5-fluorouracil, folinic acid and oxaliplatin (<i>n</i> = 24), capecitabine and oxaliplatin (<i>n</i> = 20), or 5-fluorouracil and cisplatin (<i>n</i> = 2). The primary end point was confirmed objective response rate (ORR).</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"19 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Robot-assisted laparoscopic surgery confers improved oncological outcomes. 机器人辅助腹腔镜手术可改善肿瘤预后。
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-06-17 DOI: 10.1038/s41571-025-01050-w
Peter Sidaway
{"title":"Robot-assisted laparoscopic surgery confers improved oncological outcomes.","authors":"Peter Sidaway","doi":"10.1038/s41571-025-01050-w","DOIUrl":"https://doi.org/10.1038/s41571-025-01050-w","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"623 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The next generation of immunotherapies for lung cancers 新一代的肺癌免疫疗法
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-06-17 DOI: 10.1038/s41571-025-01035-9
Shen Zhao, Hongyun Zhao, Weiwei Yang, Li Zhang
{"title":"The next generation of immunotherapies for lung cancers","authors":"Shen Zhao, Hongyun Zhao, Weiwei Yang, Li Zhang","doi":"10.1038/s41571-025-01035-9","DOIUrl":"https://doi.org/10.1038/s41571-025-01035-9","url":null,"abstract":"<p>Immunotherapies, specifically immune-checkpoint inhibitors (ICIs) targeting PD-(L)1 or CTLA4, have revolutionized the treatment of lung cancer; however, many patients do not have a response to ICIs and most of those with an initial tumour response eventually have disease progression owing to acquired resistance. Over the past few years, numerous therapeutic strategies have been explored to address the problems of intrinsic and acquired resistance to ICIs. In 2024, regulatory approvals of the bispecific PD-1 × VEGF antibody ivonescimab for the treatment of non-small-cell lung cancer in China and the bispecific DLL3 × CD3 T cell engager tarlatamab for patients with small cell lung cancer in the USA provided clinical proof-of-concept for overcoming the challenge of ICI resistance using novel immunotherapeutic agents, thereby increasing enthusiasm for the exploration of next-generation immunotherapies for lung cancer. A large variety of immunotherapies with diverse targets and mechanisms of action are currently being tested in clinical trials involving patients with lung cancer. In this Review, we provide an overview of these emerging immunotherapies in clinical development for non-small-cell lung cancer and/or small cell lung cancer, including novel immune-checkpoint modulators, immune cell engagers, adoptive cell therapies and therapeutic cancer vaccines. We describe the designs of these agents and the mechanisms by which they might overcome resistance to the current generation of ICIs. We also discuss hurdles impeding the clinical translation of each immunotherapeutic modality and potential strategies to address these challenges, using representative examples of agents that have entered the later phases of clinical testing.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"25 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144305168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adding durvalumab to perioperative FLOT improves gastric cancer outcomes. 在围手术期FLOT中加入杜伐单抗可改善胃癌预后。
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-06-17 DOI: 10.1038/s41571-025-01046-6
David Killock
{"title":"Adding durvalumab to perioperative FLOT improves gastric cancer outcomes.","authors":"David Killock","doi":"10.1038/s41571-025-01046-6","DOIUrl":"https://doi.org/10.1038/s41571-025-01046-6","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"43 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Second-line tarlatamab improves OS in SCLC. 二线塔拉他单抗改善SCLC的OS。
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-06-17 DOI: 10.1038/s41571-025-01047-5
David Killock
{"title":"Second-line tarlatamab improves OS in SCLC.","authors":"David Killock","doi":"10.1038/s41571-025-01047-5","DOIUrl":"https://doi.org/10.1038/s41571-025-01047-5","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"232 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests 液体活检检测早期检测多种癌症的前景和缺陷
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-06-13 DOI: 10.1038/s41571-025-01033-x
Jonathan C. M. Wan, Peter Sasieni, Nitzan Rosenfeld
{"title":"Promises and pitfalls of multi-cancer early detection using liquid biopsy tests","authors":"Jonathan C. M. Wan, Peter Sasieni, Nitzan Rosenfeld","doi":"10.1038/s41571-025-01033-x","DOIUrl":"https://doi.org/10.1038/s41571-025-01033-x","url":null,"abstract":"<p>Cancer screening is an essential public health intervention for diagnosing cancers at an early stage that can enable earlier treatment — ideally with curative intent — and thus lead to improved outcomes. Over the past decade, liquid biopsy-based tests have emerged as a promising, minimally invasive and broadly applicable screening approach by combining multi-cancer early detection (MCED) with tumour tissue-of-origin identification. Large-scale randomized clinical trials evaluating liquid biopsy-based MCED approaches are now under way, although whether the diagnostic performance of this first generation of MCED tests is sufficient to translate into clinical benefits remains to be determined. In this Review, we discuss the promises and pitfalls of current MCED tests and highlight possible trajectories for the field of early cancer detection.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"174 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144288632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC 在维持治疗中加入鲁比丁可改善ES-SCLC的预后
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-06-12 DOI: 10.1038/s41571-025-01043-9
Diana Romero
{"title":"Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC","authors":"Diana Romero","doi":"10.1038/s41571-025-01043-9","DOIUrl":"https://doi.org/10.1038/s41571-025-01043-9","url":null,"abstract":"<p>Patients with extensive-stage small cell lung cancer (ES-SCLC) typically receive first-line combinations of immune-checkpoint inhibitors (ICIs) and platinum-based chemotherapy followed by maintenance ICIs to limit the risk of disease progression. Now, results from the phase III IMforte trial demonstrate that the addition of lurbinectedin to maintenance therapy improves patient outcomes.</p><p>A total of 660 patients with an ongoing response or stable disease after first-line therapy were randomly allocated (1:1) to receive maintenance therapy with atezolizumab with or without lurbinectedin. Progression-free survival (PFS) and overall survival (OS) were the co-primary end points.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"151 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144278423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
T-DXd effective as second-line therapy in G/GEJ cancers T-DXd作为G/GEJ癌的二线治疗有效
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-06-12 DOI: 10.1038/s41571-025-01044-8
Peter Sidaway
{"title":"T-DXd effective as second-line therapy in G/GEJ cancers","authors":"Peter Sidaway","doi":"10.1038/s41571-025-01044-8","DOIUrl":"https://doi.org/10.1038/s41571-025-01044-8","url":null,"abstract":"<p>Patients with HER2-positive (HER2<sup>+</sup>) metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with disease progression on first-line therapy have various treatment options available, although the most-effective agent remains uncertain. Now, data from the phase III DESTINY-Gastric04 trial confirm the superiority of trastuzumab deruxtecan (T-DXd) over ramucirumab plus paclitaxel in this setting.</p><p>A total of 494 patients with disease progression on chemotherapy plus trastuzumab with or without an anti-PD-(L)1 antibody were randomized (1:1) to second-line therapy with T-DXd versus ramucirumab plus paclitaxel. Overall survival (OS) was the primary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"41 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new first-line standard-of-care for BRAFV600E-mutated mCRC brafv600e突变mCRC的新一线护理标准
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-06-12 DOI: 10.1038/s41571-025-01042-w
Diana Romero
{"title":"A new first-line standard-of-care for BRAFV600E-mutated mCRC","authors":"Diana Romero","doi":"10.1038/s41571-025-01042-w","DOIUrl":"https://doi.org/10.1038/s41571-025-01042-w","url":null,"abstract":"<p>The combination of the BRAF inhibitor encorafenib and the anti-EGFR antibody cetuximab is the standard-of-care (SOC) second-line treatment for patients with <i>BRAF</i><sup>V600E</sup>-mutated metastatic colorectal cancers (mCRC; 8–12% of patients). Now, results from the phase III BREAKWATER trial demonstrate the efficacy of encorafenib–cetuximab plus mFOLFOX6 chemotherapy as a first-line treatment for these patients.</p><p>Patients with previously untreated <i>BRAF</i><sup>V600E</sup>-mutated mCRC were randomly assigned to receive encorafenib–cetuximab, encorafenib–cetuximab plus mFOLFOX6 (triplet combination) or physician’s choice of SOC chemotherapy. After a protocol amendment, enrolment in the encorafenib–cetuximab group was stopped and patients were randomly assigned to receive triplet combination (<i>n</i> = 236) versus SOC chemotherapy (<i>n</i> = 243). Progression-free survival (PFS) and objective response rate (ORR) were the co-primary end points.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"41 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant nivolumab plus chemotherapy improves overall survival in resectable NSCLC 新辅助纳武单抗加化疗可提高可切除NSCLC患者的总生存率
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-06-12 DOI: 10.1038/s41571-025-01045-7
Peter Sidaway
{"title":"Neoadjuvant nivolumab plus chemotherapy improves overall survival in resectable NSCLC","authors":"Peter Sidaway","doi":"10.1038/s41571-025-01045-7","DOIUrl":"https://doi.org/10.1038/s41571-025-01045-7","url":null,"abstract":"<p>Earlier data from the phase III CheckMate 816 trial led to the approval of nivolumab plus platinum-doublet chemotherapy as neoadjuvant therapy for patients with resectable non-small-cell lung cancer (NSCLC). Now, 5-year follow-up data from this trial confirm that this approach improves overall survival (OS).</p><p>A total of 358 patients with stage IB–IIIA NSCLC were randomly assigned (2:1) to receive three cycles of neoadjuvant nivolumab plus chemotherapy or chemotherapy alone, followed by surgery with optional adjuvant chemotherapy and/or radiotherapy permitted in both groups. The co-primary end points (pathological complete response (pCR) rate and event-free survival (EFS)) were met at a previous cutoff; overall survival (OS) was a key secondary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"61 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信